HAZLET, N.J. - June 10, 2025 - PRLog -- In this symposium, three experts in ATTR CM (Dr. Mathew Maurer, Dr. Sarah Cuddy, and Dr. Melissa Lyle) will explain best practices for identifying and diagnosing ATTR-CM in patients with concomitant HF, describe the evidence for current ATTR-CM therapies and, through case presentation, discuss practical considerations in management.
Click here for more information
Mathew Maurer, MD
Professor of Cardiology
Columbia University
Irving Medical Center
Vagelos College of Physicians & Surgeons
New York, New York
FACULTY
Sarah Cuddy, MD
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Melissa Lyle, MD
Associate Professor of Medicine
Mayo Clinic College of Medicine
Jacksonville, Florida
Educational Objectives
- Identify clinical clues which raise suspicion for cardiac amyloidosis in HF patients
- Describe the diagnostic pearls to quickly and accurately diagnose ATTR-CM
- Assess the benefits and risks of HF medications in patients with ATTR-CM
- Summarize the evolving therapeutic landscape for ATTR-CM
Target Audience
This educational activity is intended for clinicians who manage patients with heart failure.
Educational Grant
Voxmedia gratefully acknowledges the independent educational grant provided by Alnylam Pharmaceuticals, Inc.
Accreditation and Credit Designation Statements
Voxmedia, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Voxmedia, LLC designates this live activity for a maximum of 1.0 AMA PRA Category Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements. The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Photos: (Click photo to enlarge)
Source: CMEPlanet
Read Full Story - 2025 HFM Symposium - Optimizing the Management of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in Patients with Heart Failure | More news from this source
Press release distribution by PRLog